Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

NCT05699655 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

130

Enrollment

OTHER_GOV

Sponsor class

Conditions

Immunotherapy Gastrict Cancer

Interventions

DRUG: Tislelizumab
DRUG: apatinib
DRUG: oxaliplatin
DRUG: S-1

Sponsor

Fujian Cancer Hospital